Quavonlimab (MK-1308) is a novel human monoclonal antibody designed to selectively target and block the immune checkpoint molecule cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), investigation of quavonlimab in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) has shown encouraging anti-tumor activity along with an acceptable safety profile,making it an interesting compound for the reasearches into advanced non-small cell lung cancer (NSCLC).